Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has announced that its common shares have been approved for electronic clearing and settlement through the Depository Trust Company (DTC). This development is expected to simplify trading for U.S. investors and enhance the liquidity of the company's shares. CEO Louis Dron stated that DTC eligibility improves access for U.S. investors and brokerage firms by enabling more efficient electronic clearing and settlement, which could broaden the shareholder base and potentially increase trading volume.
In a separate announcement, Redwood AI engaged InvestorBrandNetwork (IBN) to provide market awareness, corporate communications, and digital media services. The engagement includes editorial coverage, newsletter distribution, social media support, and podcast syndication through September 30, 2026, or until the allocated budget is exhausted. Redwood will pay IBN an aggregate cash fee of $114,000 for these services, with no securities issued as compensation. This partnership is part of Redwood's strategy to increase its visibility among investors and the broader financial community.
The company's DTC eligibility is a significant milestone, as it streamlines the process for U.S. investors to buy and sell shares. DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC) that provides clearing and settlement services for the U.S. securities markets. By participating in DTC, Redwood's shares can be electronically processed, reducing paperwork and settlement times. This is particularly important for small-cap companies seeking to attract institutional investors, who often require DTC eligibility for efficient trading.
Redwood AI uses advanced artificial intelligence to accelerate chemistry research and development, with a focus on drug discovery, development, and defense applications. The company's platform combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. This technology aims to enable faster, more efficient development of new therapies and chemistry-driven solutions. The recent announcements align with Redwood's efforts to strengthen its market position and attract investment as it advances its AI-driven platform.
For more information, visit Redwood AI's website or view the full press release here.
